Advertisement

Cardiotoxicity During and After Breast Cancer Treatment

  • Angela H. E. M. MaasEmail author
Chapter

Abstract

As cardiovascular diseases (CVD) are the main cause of death in women worldwide, they are also frequently present in breast cancer (BC) patients and in late survivors. Radiation therapy, chemotherapy, immunotherapy and angiogenic therapy may induce cardiotoxicity and vascular damage. In the rapidly evolving field of cardio-oncology it is recommended that pre-existing CVD risk factors should be assessed in all BC patients and aggressively managed, starting at the time of treatment (or even before) and continuing throughout survivorship. The use of advanced cardiac imaging techniques improves earlier detection of cardiac damage and heart failure, enabling a more timely treatment.

Keywords

Anthracyclines Blood pressure BRCA 1/2 mutation carriers Breast cancer Cardiotoxicity Cardio-oncology Chemotherapy Ejection fraction Immunotherapy Systolic heart failure Radiation therapy Risk factors Trastuzumab 

References

  1. 1.
    Barac A, et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol. 2015;65(25):2739–46.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–67.CrossRefPubMedGoogle Scholar
  3. 3.
    Bardia A, et al. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat. 2012;131(3):907–14.CrossRefPubMedGoogle Scholar
  4. 4.
    Calle EE, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.CrossRefPubMedGoogle Scholar
  5. 5.
    Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121(4):856–62.CrossRefPubMedGoogle Scholar
  6. 6.
    Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr. 2007;86(3):s823–35.PubMedGoogle Scholar
  7. 7.
    Hooning MJ, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365–75.CrossRefPubMedGoogle Scholar
  8. 8.
    Jones LW, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007;50(15):1435–41.CrossRefPubMedGoogle Scholar
  9. 9.
    Lal H, Kolaja KL, Force T. Cancer genetics and the cardiotoxicity of the therapeutics. J Am Coll Cardiol. 2013;61(3):267–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Pavo N, et al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015;101(23):1874–80.CrossRefPubMedGoogle Scholar
  11. 11.
    Maas AH, et al. Cardiovascular surveillance in breast cancer treatment: a more individualized approach is needed. Maturitas. 2016;89:58–62.CrossRefPubMedGoogle Scholar
  12. 12.
    Zamorano JL, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801.CrossRefPubMedGoogle Scholar
  13. 13.
    Antoniou A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Arts-de Jong M, et al. BRCA1/2 mutation carriers are potentially at higher cardiovascular risk. Crit Rev Oncol Hematol. 2014;91(2):159–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Mai PL, et al. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma. PLoS One. 2009;4(3):e4812.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    van Westerop LL, et al. Cardiovascular risk of BRCA1/2 mutation carriers: a review. Maturitas. 2016;91:135–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Singh KK, et al. BRCA2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure. J Biol Chem. 2012;287(9):6604–14.CrossRefPubMedGoogle Scholar
  18. 18.
    Barac A, et al. Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. Breast Cancer Res Treat. 2016;155(2):285–93.CrossRefPubMedGoogle Scholar
  19. 19.
    Bouillon K, et al. Long-term cardiovascular mortality after radiotherapy for breast cancer. J Am Coll Cardiol. 2011;57(4):445–52.CrossRefPubMedGoogle Scholar
  20. 20.
    Nilsson G, et al. Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol. 2012;30(4):380–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Darby SC, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.CrossRefPubMedGoogle Scholar
  22. 22.
    Swanson T, et al. Six-year experience routinely using moderate deep inspiration breath-hold for the reduction of cardiac dose in left-sided breast irradiation for patients with early-stage or locally advanced breast cancer. Am J Clin Oncol. 2013;36(1):24–30.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Mast ME, et al. Left-sided breast cancer radiotherapy with and without breath-hold: does IMRT reduce the cardiac dose even further? Radiother Oncol. 2013;108(2):248–53.CrossRefPubMedGoogle Scholar
  24. 24.
    Essers M, et al. Should breathing adapted radiotherapy also be applied for right-sided breast irradiation? Acta Oncol. 2016;55(4):460–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34(15):1102–11.CrossRefPubMedGoogle Scholar
  26. 26.
    Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res. 2016;118(6):1008–20.CrossRefPubMedGoogle Scholar
  27. 27.
    Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007;49(5):330–52.CrossRefPubMedGoogle Scholar
  28. 28.
    Cardinale D, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Chen J, et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504–12.CrossRefPubMedGoogle Scholar
  30. 30.
    Procter M, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010;28(21):3422–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Farolfi A, et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart. 2013;99(9):634–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Slamon D, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Romond EH, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.CrossRefPubMedGoogle Scholar
  34. 34.
    Suter TM, et al. Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trial. J Clin Oncol. 2007;25(25):3859–65.CrossRefPubMedGoogle Scholar
  35. 35.
    Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34.CrossRefPubMedGoogle Scholar
  36. 36.
    Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6(8):465–77.CrossRefPubMedGoogle Scholar
  37. 37.
    Li W, et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol. 2015;66(10):1160–78.CrossRefPubMedGoogle Scholar
  38. 38.
    Cameron D, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14(10):933–42.CrossRefPubMedGoogle Scholar
  39. 39.
    Bonanni B, et al. Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women. J Thromb Haemost. 2003;1(10):2149–52.CrossRefPubMedGoogle Scholar
  40. 40.
    Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol. 2014;142:142–54.CrossRefPubMedGoogle Scholar
  41. 41.
    Davies C, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Ryden L, et al. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo – meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast. 2016;26:106–14.CrossRefPubMedGoogle Scholar
  43. 43.
    Amir E, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299–309.CrossRefPubMedGoogle Scholar
  44. 44.
    Chlebowski RT, et al. Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. Breast Cancer Res Treat. 2015;154(3):609–16.CrossRefPubMedGoogle Scholar
  45. 45.
    Lintermans A, Neven P. Safety of aromatase inhibitor therapy in breast cancer. Expert Opin Drug Saf. 2015;14(8):1201–11.CrossRefPubMedGoogle Scholar
  46. 46.
    Kerkhove D, et al. How to monitor cardiac toxicity of chemotherapy: time is muscle! Heart. 2014;100(15):1208–17.CrossRefPubMedGoogle Scholar
  47. 47.
    Thavendiranathan P, et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77–84.CrossRefPubMedGoogle Scholar
  48. 48.
    Walker J, et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol. 2010;28(21):3429–36.CrossRefPubMedGoogle Scholar
  49. 49.
    Plana JC, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063–93.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Curigliano G, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012;23(Suppl 7):vii155–66.CrossRefPubMedGoogle Scholar
  51. 51.
    Gulati G, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671–80.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Seicean S, et al. Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6(3):420–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Cardiology, Women’s Cardiac Health ProgramRadboud University Medical CenterNijmegenThe Netherlands

Personalised recommendations